Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | NCF1 | P14598 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | RHOA | P61586 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23405733 | 0.91 | KDM4E (0.36) | GRM5KDM4EGPR3NCF1ADRB2 | |
| SCHEMBL30079947 | 0.91 | KDM4E (0.36) | GRM5KDM4EGPR3NCF1ADRB2 | |
| SCHEMBL25666745 | 0.79 | LMNA (0.37) | GRM5KDM4EADRA2AADRA2CADRA1D | |
| SCHEMBL9590061 | 0.79 | GRM1 (0.41) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL13652212 | 0.76 | NCF1 (0.44) | KDM4EADRA1DADRA1AADRA1BNCF1 | |
| SCHEMBL30079880 | 0.75 | KDM4E (0.36) | KDM4EGPR3NCF1ADRB2ALDH1A1 | |
| SCHEMBL25666758 | 0.75 | KDM4E (0.36) | KDM4EGPR3NCF1ADRB2ALDH1A1 | |
| SCHEMBL22744581 | 0.75 | SSTR4 (0.36) | GRM5KDM4EGPR3NCF1ADRB2 | |
| SCHEMBL1191697 | 0.74 | KDM4E (0.38) | GRM5KDM4EGPR3NCF1ADRB2 | |
| SCHEMBL25666734 | 0.73 | KDM4E (0.42) | KDM4EGPR3ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4743601-A | MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-10 | — | — | US | claimed |
| WO-2023109909-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-11512095-B2 | BCL6 inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-29 | — | — | US | disclosed |
| US-5182275-A | Intermediates for memory enhancers | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-01-26 | — | — | US | disclosed |
| US-4942168-A | INTERMEDIATES FOR 1,2-DIHYDRO-3-METHYL-3H-1,4-OXAZINO 2,3-C!QU INOLINE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0299345-A3 | Dihydro-1,4-oxazino(2,3-c)quinolines, a process and intermediates for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-06-13 | — | — | EP | disclosed |
| EP-0299345-A2 | Dihydro-1,4-oxazino(2,3-c)quinolines, a process and intermediates for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0299345-A2 | Dihydro-1,4-oxazino(2,3-c)quinolines, a process and intermediates for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-18 | — | — | EP | disclosed |
| US-4743601-A | MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-10 | — | — | US | disclosed |
| US-4743601-A | MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512095-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | GRM5 4476/4885KDM4E 481/4885GPR3 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.